Annunziata CM,Stavnes HT,Kleinberg L,et al.Nuclear factor kappaB transcription factors are coexpressed and convey a poor outcome in ovarian cancer [J].Cancer,2010,116(13):3276-3284.
[2]
Maeda S,Omata M.Inflammation and cancer:role of nuclear factor-kappaB activation [J].Cancer Sci,2008,99(5):836-842.
[3]
Risch HA,McLaughlin JR,Cole DE,et al.Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer [J].Am J Hum Genet,2001,68(3):700-710.
[4]
Hernandez L,Hsu SC,Davidson B,et al.Activation of NF-kappaB signaling by inhibitor of NF-kappaB kinase beta increases aggressiveness of ovarian cancer [J].Cancer Res,2010,70(10):4005-4014.
[5]
Tang T,Cui S,Deng X,et al.Insertion/deletion polymorphism in the promoter region of NFKB1 gene increases susceptibility for superficial bladder cancer in Chinese [J].DNA Cell Biol,2010,29(1):9-12.
[6]
Karban AS,Okazaki T,Panhuysen CI,et al.Functional annotation of a novel NFKB1 promoter polymorphism that increases risk for ulcerative colitis [J].Hum Mol Genet,2004,13(1):35-45.
[7]
Jemal A,Siegel R,Ward E,et al.Cancer statistics [J].CA Cancer J Clin,2008,58(2):71-96.
[8]
Karin M.Nuclear factor-kappaB in cancer development and progression [J].Nature,2006,441(7092):431-436.
[9]
Lin YG,Kunnumakkara AB,Nair A,et al.Curcumin inhibits tumor growth and angiogenesis in ovarian carcinoma by targeting the nuclear factor-kappaB pathway [J].Clin Cancer Res,2007,13(11):3423-3430.
